275 related articles for article (PubMed ID: 28591041)
1. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
2. Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg Seroconversion.
Wang ML; Zhou QL; Chen EQ; Du LY; Yan LB; Bai L; He M; Tang H
Viral Immunol; 2016; 29(6):332-42. PubMed ID: 27104358
[TBL] [Abstract][Full Text] [Related]
3. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
5. [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
Pan XC; Yang F; Chen M
Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):885-8. PubMed ID: 19105929
[TBL] [Abstract][Full Text] [Related]
6. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
7. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
8. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
Li J; Jia M; Liu Y; She W; Li L; Wang J; Jiang W
Liver Int; 2015 Mar; 35(3):834-45. PubMed ID: 24814578
[TBL] [Abstract][Full Text] [Related]
9. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B.
Su ZJ; Yu XP; Guo RY; Ming DS; Huang LY; Su ML; Deng Y; Lin ZZ
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):437-44. PubMed ID: 23747030
[TBL] [Abstract][Full Text] [Related]
10. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
12. The serum interleukin-26 level is a potential biomarker for chronical hepatitis B.
Luo L; Jiang L; Tian Z; Zhang X
Medicine (Baltimore); 2020 Jan; 99(1):e18462. PubMed ID: 31895778
[TBL] [Abstract][Full Text] [Related]
13. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
14. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks.
Wang J; Du LY; Zhu X; Chen EQ; Tang H
Indian J Med Microbiol; 2015 Feb; 33 Suppl():20-5. PubMed ID: 25657151
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
18. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-β1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis.
Yu X; Guo R; Ming D; Su M; Lin C; Deng Y; Lin Z; Su Z
J Gastroenterol Hepatol; 2014 May; 29(5):1065-72. PubMed ID: 24236690
[TBL] [Abstract][Full Text] [Related]
19. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment.
Zhang JY; Song CH; Shi F; Zhang Z; Fu JL; Wang FS
PLoS One; 2010 Nov; 5(11):e13869. PubMed ID: 21079784
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
